# Competitive Pipeline Report — Johnson & Johnson

## Run coverage & provenance
- Run date (UTC): 2026-01-08
- Pipeline source URL: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
- Stored pipeline PDF: `sources/jnj/2026-01-08.pdf`
- Pipeline SHA256: `7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04`
- Programs extracted: 101
- Note: Source PDF unchanged; reused prior snapshot to avoid extraction variability.
- Inventory export: `reports/jnj/2026-01-08.programs.csv`
- Evidence pack: `reports/jnj/2026-01-08.evidence.json`

## Executive summary
**Quiet Month: No Major Competitor Pipeline Shifts Detected**

This month's competitive intelligence update reflects a period of low reported activity among key competitors. Our automated monitoring systems, covering clinical trial registries, regulatory filings (SEC), and corporate press releases, did not detect any significant new pipeline assets, major phase advancements, strategic deals, or unexpected discontinuations within the reporting period. While our internal CT.gov monitoring for J&J's own assets remains active, external competitive signals were minimal. We maintain vigilance on high-priority areas and specific competitor programs.

## Top changes (ranked)
_No ranked changes generated._

## Change log (previous vs current)
### New / Added items
_None detected._

### Removed / Discontinued items
_None detected._

### Phase changes
_None detected._

## ClinicalTrials.gov corroboration
- API base: https://clinicaltrials.gov/api/v2
- Programs with matches: 32/101
- Phase mismatches (pipeline vs registry): 0
- Stored CT.gov evidence: `sources/jnj/ctgov/2026-01-08`

## SEC EDGAR signals
- Filings since: 2025-10-10
- New filings processed this run: 0
- Filings with extracted events: 0
- Stored EDGAR evidence: `sources/jnj/sec/2026-01-08`

_No recent filings list stored for this run._

## IR press release signals
- Feed URL: https://www.jnj.com/rss-feed/all
- Links scanned: 10
- New releases processed: 0
- Releases with extracted events: 0
- Previously processed releases skipped: 10
- Stored press evidence: `sources/jnj/press/2026-01-08`

### Latest press releases (coverage)
- 2026-01-08 — already processed — Johnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-celebrates-innovation-in-cancer-research-with-2025-dr-paul-janssen-award
- 2026-01-07 — already processed — Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration
- 2026-01-06 — already processed — Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-application-to-the-european-medicines-agency-for-tecvayli-teclistamab-in-combination-with-darzalex-daratumumab-subcutaneous-formulation-for-patients-with-relapsed-refractory-multiple-myeloma
- 2026-01-06 — already processed — Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-unveils-new-data-showing-nipocalimab-is-the-first-and-only-investigational-fcrn-blocker-with-potential-to-reduce-systemic-lupus-erythematosus-sle-activity-in-a-phase-2-study
- 2026-01-02 — already processed — Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2026
- 2025-12-29 — already processed — Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-halda-therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies
- 2025-12-26 — already processed — Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-the-phase-2b-duplex-ad-study
- 2025-12-22 — already processed — European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
  - https://www.jnj.com/media-center/press-releases/european-commission-approves-tremfya-guselkumab-for-the-treatment-of-children-with-plaque-psoriasis-marking-the-first-paediatric-indication-for-an-il-23-inhibitor
- 2025-12-19 — already processed — Johnson & Johnson Backs HRS Registry to Advance Real-World Evidence in PFA
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-backs-hrs-registry-to-advance-real-world-evidence-in-pfa
- 2025-12-18 — already processed — Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-fda-approval-for-trufill-n-bca-liquid-embolic-system-for-the-treatment-of-symptomatic-chronic-subdural-hematoma

_No pipeline-relevant press signals extracted in this run._

## Pipeline inventory (full list)
| Asset | Indication | Phase | Page | CT.gov phase | Flag |
|---|---|---|---:|---|---|
| AKEEGA (niraparib/abiraterone) | M1 Metastatic Castration-Sensitive Prostate Cancer |  |  | Phase 3 | ok |
| Bleximenib | Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine |  |  | Phase 3 | ok |
| Bleximenib | Relapsed Refractory Acute Myeloid Leukemia |  |  | Phase 3 | ok |
| CABENUVA | HIV Adolescents |  |  |  | none |
| CAPLYTA (lumateperone) | Adjunctive Treatment for Major Depressive Disorder |  |  |  | none |
| CAPLYTA (lumateperone) | Bipolar Mania |  |  |  | none |
| CAPLYTA (lumateperone) | Pediatric Psychiatric Indications |  |  |  | none |
| CARVYKTI (Ciltacabtagene autoleucel) | Frontline Multiple Myeloma TNI |  |  | Phase 3 | ok |
| CARVYKTI (Ciltacabtagene autoleucel) | Frontline Multiple Myeloma Transplant Eligible vs ASCT |  |  | Phase 3 | ok |
| DARZALEX (daratumumab) | Smoldering Multiple Myeloma |  |  | Phase 3 | ok |
| DARZALEX (daratumumab) | Frontline multiple myeloma transplant ineligible |  |  | Phase 3 | ok |
| ERLEADA (apalutamide) | Localized Prostate Cancer |  |  | Phase 3 | ok |
| ERLEADA (apalutamide) | High Risk Prostate Cancer |  |  | Phase 3 | ok |
| IMAAVY (nipocalimab) | Generalized Myasthenia Gravis |  |  |  | none |
| IMAAVY (nipocalimab) | Generalized Myasthenia Gravis Pediatrics |  |  |  | none |
| IMBRUVICA (ibrutinib) | Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) |  |  | Phase 3 | ok |
| IMBRUVICA (ibrutinib) | Frontline Mantle Cell Lymphoma |  |  | Phase 3 | ok |
| INLEXZO (gemcitabine intravesical system) | Non Muscle Invasive Bladder Cancer |  |  | Phase 3 | ok |
| INLEXZO (gemcitabine intravesical system) | Non Muscle Invasive Bladder Cancer BCG-naïve High Risk |  |  | Phase 3 | ok |
| INLEXZO (gemcitabine intravesical system) | High Risk Non Muscle Invasive Bladder Cancer BGC Experienced |  |  | Phase 3 | ok |
| ITI-1284 | Generalized Anxiety Disorder |  |  |  | none |
| ITI-1284 | Alzheimer's Disease-Related Psychosis |  |  |  | none |
| ITI-1284 | Alzheimer's Disease-Related Agitation |  |  |  | none |
| JNJ-0387 | Solid Tumors |  |  |  | none |
| JNJ-0631 (ARX305) | Renal Cancer |  |  |  | none |
| JNJ-0683 (ARX788) | Breast Cancer |  |  | Phase 3 | ok |
| JNJ-1493 | Hematological Malignancies |  |  |  | none |
| JNJ-1887 sCD59 | Geographic Atrophy |  |  |  | none |
| JNJ-1900 (NBTXR3) | Head and Neck Cancer |  |  | Phase 3 | ok |
| JNJ-1900 (NBTXR3) | Lung Cancer |  |  | Phase 3 | ok |
| JNJ-2056 (tau active immunotherapy) | Alzheimer's Disease |  |  |  | none |
| JNJ-2638 | Gastrointestinal Cancer |  |  |  | none |
| JNJ-2761 | Multiple Myeloma |  |  |  | none |
| JNJ-3413 | Lymphoma |  |  |  | none |
| JNJ-4496 | Hematological Malignancies |  |  |  | none |
| JNJ-4680 | Lung Cancer |  |  |  | none |
| JNJ-4681 | Hematological Malignancies |  |  |  | none |
| JNJ-4804 Co-antibody Therapy | Ulcerative Colitis |  |  |  | none |
| JNJ-4804 Co-antibody Therapy | Psoriatic Arthritis |  |  |  | none |
| JNJ-4804 Co-antibody Therapy | Crohn's Disease |  |  |  | none |
| JNJ-4916 | Lung Cancer |  |  |  | none |
| JNJ-5108 | Immunological Diseases |  |  |  | none |
| JNJ-5120 | Major Depressive Disorder |  |  |  | none |
| JNJ-5322 | Multiple Myeloma |  |  |  | none |
| JNJ-5939 | Atopic Dermatitis |  |  |  | none |
| JNJ-6420 | Prostate Cancer |  |  |  | none |
| JNJ-6848 | Immunological Diseases |  |  |  | none |
| JNJ-7446 | Lung Cancer |  |  |  | none |
| JNJ-7528 | Atopic Dermatitis |  |  |  | none |
| JNJ-8177 (ARX517) | Prostate Cancer |  |  |  | none |
| JNJ-8377 | Lymphoma |  |  |  | none |
| JNJ-8543 | Hematological Malignancies |  |  |  | none |
| JNJ-9401 | Prostate Cancer |  |  |  | none |
| JNJ-9530 | Hematological Malignancies |  |  |  | none |
| JNJ-9892 | Hematological Malignancies |  |  |  | none |
| JNJ-9968 | Hematological Malignancies |  |  |  | none |
| RPGR Gene Therapy | Retinitis Pigmentosa |  |  |  | none |
| RYBREVANT (amivantamab) | Frontline Non Small Cell Lung Cancer in combination with chemotherapy |  |  | Phase 3 | ok |
| RYBREVANT (amivantamab) |  |  |  | Phase 3 | ok |
| RYBREVANT (amivantamab) | Colorectal Cancer |  |  | Phase 3 | ok |
| RYBREVANT (amivantamab) | Colorectal Cancer 2L |  |  | Phase 3 | ok |
| SIMPONI (golimumab) | Pediatric Ulcerative Colitis |  |  |  | none |
| SIRTURO | Leprosy |  |  |  | none |
| SIRTURO | Tuberculosis Long Acting |  |  |  | none |
| SPRAVATO (esketamine) | Treatment Resistant Depression monotherapy |  |  |  | none |
| SPRAVATO (esketamine) | Major Depressive Disorder with Suicidal Ideation Pediatrics |  |  |  | none |
| STELARA (ustekinumab) | Pediatric Crohn's Disease |  |  |  | none |
| STELARA (ustekinumab) | Pediatric Ulcerative Colitis |  |  |  | none |
| TALVEY (talquetamab) | Relapsed Refractory Multiple Myeloma CD38 exposed |  |  | Phase 3 | ok |
| TALVEY (talquetamab) | Relapsed Refractory Multiple Myeloma A-CD38 Naïve |  |  | Phase 3 | ok |
| TALVEY + TECVAYLI | Relapsed Refractory Multiple Myeloma CD38 exposed |  |  | Phase 3 | ok |
| TALVEY + TECVAYLI | TIE NDMM in combination with DR |  |  | Phase 3 | ok |
| TALVEY + TECVAYLI | Relapsed Refractory Multiple Myeloma |  |  | Phase 3 | ok |
| TAR-210 (RIS/erdafitinib) | Intravesical Delivery System for Localized Bladder Cancer |  |  | Phase 3 | ok |
| TECVAYLI (teclistamab) | Multiple Myeloma 1-3PLs |  |  | Phase 3 | ok |
| TECVAYLI (teclistamab) | TE NDMM maintenance |  |  | Phase 3 | ok |
| TECVAYLI (teclistamab) | TIE NDMM in combination with DR |  |  | Phase 3 | ok |
| TECVAYLI (teclistamab) | Relapsed Refractory Multiple Myeloma CD38 exposed |  |  | Phase 3 | ok |
| TREMFYA (guselkumab) | Pediatric Juvenile Psoriatic Arthritis |  |  |  | none |
| TREMFYA (guselkumab) | Pediatric Psoriasis |  |  |  | none |
| TREMFYA (guselkumab) | Psoriatic Arthritis Structural Damage |  |  |  | none |
| TREMFYA (guselkumab) | Ulcerative Colitis Subcutaneous Induction |  |  |  | none |
| TREMFYA (guselkumab) | Pediatric Ulcerative Colitis |  |  |  | none |
| UPTRAVI (selexipag) | Pediatric Pulmonary Arterial Hypertension |  |  |  | none |
| icotrokinra | Psoriasis |  |  |  | none |
| icotrokinra | Psoriatic Arthritis |  |  |  | none |
| icotrokinra | Ulcerative Colitis |  |  |  | none |
| macitentan | Pulmonary Arterial Hypertension 75mg |  |  |  | none |
| milvexian (Factor Xla) | Secondary Stroke Prevention |  |  |  | none |
| milvexian (Factor Xla) | Acute Coronary Syndrome |  |  |  | none |
| milvexian (Factor Xla) | Atrial Fibrillation |  |  |  | none |
| nipocalimab | Warm Autoimmune Hemolytic Anemia |  |  |  | none |
| nipocalimab | Sjogren's Disease |  |  |  | none |
| nipocalimab | Hemolytic Disease of the Fetus and Newborn |  |  |  | none |
| nipocalimab | Fetal and Neonatal Alloimmune Thrombocytopenia |  |  |  | none |
| nipocalimab | Systemic Lupus Erythematosus |  |  |  | none |
| nipocalimab | Idiopathic Inflammatory Myopathy |  |  |  | none |
| nipocalimab | Chronic Inflammatory Demyelinating Polyneuropathy |  |  |  | none |
| pasritamig | Prostate Cancer |  |  | Phase 3 | ok |
| posdinemab | Alzheimer's Disease |  |  |  | none |
| seltorexant | Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms |  |  |  | none |
